Position in TNGX
as of Mar 31, 2026
· filed Apr 23, 2026
Position Value
$32,426
+$20,908 QoQ
Shares Held
1,550
+19.2% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in TNGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026TFC Financial Management, Inc. holds $402,102 across 44 Biotechnology names. TNGX ranks #4 (8.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
307 | $137,087 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
104 | $80,354 | |
| 3 | CRSP |
CRISPR Therapeutics AG
|
688 | $32,728 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
This page
|
1,550 | $32,426 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
72 | $23,822 | |
| 6 | MRNA |
Moderna, Inc.
|
319 | $16,205 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
211 | $13,636 | |
| 8 | OCUL |
Ocular Therapeutix, Inc
|
1,352 | $11,451 |
All Filings in TNGX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $32,426 | 1,550 | Shares | Sole | 2026-04-23 | |
| 2025-12-31 | $11,518 | 1,300 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $6,720 | 800 | Shares | Sole | 2025-10-24 | |
| 2025-06-30 | $1,536 | 300 | Shares | Sole | 2025-07-29 | |
| 2025-03-31 | $411 | 300 | Shares | Sole | 2025-04-24 | |
| 2024-12-31 | $927 | 300 | Shares | Sole | 2025-01-29 | |
| 2024-09-30 | $2,310 | 300 | Shares | Sole | 2024-10-25 | |
| No filing history on record for this holder in this stock. | ||||||